Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 71-82

  Dambacher, Julia ^a   Staudinger, Tanja ^a   Seiderer, Julia ^a   Sisic, Zeljka ^a   Schnitzler, Fabian ^a   Pfennig, Simone ^a   Hofbauer, Katrin ^a   Konrad, Astrid ^a   Tillack, Cornelia ^a   Otte, Jan Michel ^b   Diebold, Joachim ^a   Göke, Burkhard ^a   Ochsenkühn, Thomas ^a   Lohse, Peter ^a   Brand, Stephan ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cytokine; Genetics of Crohn's disease; Inflammatory bowel disease; Macrophage migration inhibitory factor (MIF); Polymorphism

Indexed keywords

CYTOKINE; MESSENGER RNA; MIGRATION INHIBITION FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFLAMMATION; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; MIF GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UPPER GASTROINTESTINAL TRACT; WILD TYPE;

ADOLESCENT; ADULT; CROHN DISEASE; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; UPPER GASTROINTESTINAL TRACT;

EID: 33846171221     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20008     Document Type: Article

References (55)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Baugh JA, Donnelly SC. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol. 2003;179:15-23.
3. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791-800.
4. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 1966;153:80-82.
5. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 1966;56:72-77.
6. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med. 2002;30:S27-35.
7. Maaser C, Eckmann L, Paesold G, Kim HS, Kagnoff MF. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterologe. 2002;122:667-680.
8. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179:1895-18902.
9. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol. 1997;158:5514-5517.
10. Onodera S, Tanji H, Suzuki K, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 1999;11:163-167.
11. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999;189:341-346.
12. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000;6:164-170.
13. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med. 1997;3:320-323.
14. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001;2:1061-1066.
15. Ohkawara T, Nishihira J, Takeda H, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroentemlogy. 2002;123:256-270.
16. Ohkawara T, Miyashita K, Nishihira J, et al. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol. 2005;140:241-248.
17. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
18. Hugot JP, Chamaillaird M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
19. Ogura Y, Bonen D, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
20. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254-258.
21. Brand S, Hofbauer K, Dambacher J, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol. 2006;101:99-106.
22. Donn RP, Shelley E, Ollier WE, Thomson W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2001;44:1782-1785.
23. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398-1407.
24. Nohara H, Okayama N, Inoue N, et al. Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol. 2004;39:242-246.
25. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
26. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(Suppl 1):i1-15.
27. Herrmann KA, Zech CJ, Michaely HJ, et al. Comprehensive magnetic resonance imaging of the small and large bowel using intraluminal dual contrast technique with iron oxide solution and water in magnetic resonance enteroclysis. Invest Radiol. 2005;40:621-629.
28. Herrmann KA, Michaely HJ, Seiderer J, Ochsenkuehn T, Reiser MF, Schoenberg SO. The "star-sign" in magnetic resonance enteroclysis: a characteristic finding of internal fistulae in Crohn's disease. Scand J Gastroenterol. 2006;41:239-241.
29. Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like receptor $rAsp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005;11:645-652.
30. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroentemlogy. 1976;70:439-444.
31. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut. 1999;44:625-628.
32. Heresbach D, Gicquel-Douabin V, Birebent B, et al. NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype-phenotype analysis. Eur J Gastroenterol Hepatol. 2004;16:55-62.
33. Helio T, Halme L, Lappalainen M, et al. CARDI5/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003;52:558-562.
34. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122:854-866.
35. Ferreira AC, Almeida S, Tavares M, et al. NOD2/CAÄD/3 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. Inflamm Bowel Dis. 2005;11:331-339.
36. Seiderer J, Schnitzler F, Brand S, et al. Homozygosity for the CARD15 frameshift mutation 1007fs predicts early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006 (in press).
37. Mardini HE, Gregory KJ, Nasser M, et al. Gastroduodenal Crohn's disease is associated with NOD2/CARD15 gene polymorphisms, particularly L1007P homozygosity. Dig Dis Sci. 2005;50:2316-2322.
38. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122:1808-1814.
39. Fielding JF, Toye DK, Beton DC, Cooke WT. Crohn's disease of the stomach and duodenum. Gut. 1970;11:1001-1006.
40. Jones GW Jr, Dooley MR, Schoenfield LJ. Regional enteritis with involvement of the duodenum. Gastroenterology. 1966;51:1018-1022.
41. Legge DA, Carlson HC, Judd ES. Roentgenologic features of regional enteritis of the upper gastrointestinal tract. Am J Roentgenol Radium Ther Nucl Med. 1970;110:355-360.
42. Frandsen PJ, Jarnum S, Malmstrom J. Crohn's disease of the duodenum. Scand J Gastroenterol 1980;15:683-688.
43. Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. Am J Gastroenterol. 1989;84:249-254.
44. Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn's disease: a prospective study. J Gastroenterol Hepatol. 1991;6:355-358.
45. Korelitz BI, Waye JD, Kreuning J, et al. Crohn's disease in endoscopic biopsies of the gastric antrum and duodenum. Am J Gastroenterol. 1981;76:103-109.
46. Lenaerts C, Roy CC, Vaillancourt M, Weber AM, Morin CL, Seidman E. High incidence of upper gastrointestinal tract involvement in children with Crohn disease. Pediatrics. 1989;83:777-781.
47. Rutgeerts P, Onette E, Vantrappen G, Geboes K, Broeckaert L, Talloen L. Crohn's disease of the stomach and duodenum: a clinical study with emphasis on the value of endoscopy and endoscopic biopsies. Endoscopy. 1980;12:288-294.
48. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
49. Yao K, Iwashita A, Yao T, et al. Increased numbers of macrophages in noninflamed gastroduodenal mucosa of patients with Crohn's disease. Dig Dis Sci. 1996;41:2260-2267.
50. Donn R, Alourfi Z, De Benedetti F, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2402-2409.
51. Murakami H, Akbar SM, Matsui H, Onji M. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001;31:337-343.
52. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724-2729.
53. Wilson JM, Coletta PL, Cuthbert RJ, et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 2005;129:1485-1503.
54. Patel M, Banerjee B, Block JG, Marshall JB. Gastric Crohn's disease complicated by adenocarcinoma of the stomach: case report and review of the literature. Am J Gastroenterol. 1997;92:1368-1371.
55. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia HH. Increased epithelial and serum expression of macrophage migration inhibitory factor in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 2006;55:797-802.